TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27550876

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg once a day for 3 days after UDS
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo (nontreated patients)
Number of subjects: 126
Study: 24877603

Group type: EXPERIMENTAL
Intervention: CHoR protocol (preoperative erythropoietin and iron therapy, intraoperative blood recycling device, lower hemoglobin trigger < 7 g/dl)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CHoR protocol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (surgery prior to protocol implementation)
Number of subjects: 60
Study: 22369484

Group type: EXPERIMENTAL
Intervention: Repeated near-infrared (NIR) light irradiation with fractionated administration of panitumumab-IR700 conjugate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single NIR light irradiation
Number of subjects: 0
Study: 19660388

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 25

Group type: COMPARATOR
Intervention: No Bosentan
Number of subjects: 25
Study: 19808265

Group type: EXPERIMENTAL
Intervention: Nesiritide (2-microg/kg bolus plus 0.01-microg/kg-per-minute infusion for 4 to 6 hours, once or twice weekly for 12 weeks)
Number of subjects: 911

Group type: COMPARATOR
Intervention: Placebo (matching placebo, once or twice weekly for 12 weeks)
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 911
Study: 16060245

Group type: EXPERIMENTAL
Intervention: Endovascular therapy for unruptured cerebral aneurysms
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Endovascular therapy for aneurysms between 5 to 10 mm
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Endovascular therapy for aneurysms between 11 to 25 mm
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Endovascular therapy for aneurysms smaller than 5 mm
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Endovascular therapy for aneurysms between 5 to 10 mm (follow-up)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Endovascular therapy for aneurysms between 10 to 24 mm (follow-up)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Endovascular therapy overall
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Endovascular therapy for a large basilar tip aneurysm
Number of subjects: 76
Study: 12353632

Group type: EXPERIMENTAL
Intervention: Medium-chain triacylglycerols (MCTs)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Long-chain triacylglycerols (blended vegetable oil)
Number of subjects: 11
Study: 10364012

Group type: EXPERIMENTAL
Intervention: Retrosternal reconstruction
Number of subjects: 26

Group type: COMPARATOR
Intervention: Posterior mediastinal reconstruction
Number of subjects: 26
Study: 7793449

Group type: EXPERIMENTAL
Intervention: 35% carbon dioxide (CO2) challenge
Number of subjects: 18
Study: 1842506

Group type: EXPERIMENTAL
Intervention: 3HEZ2/3HE2 (non‐complicated forms)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: 3HRZ2/3HR2 (complicated forms)
Number of subjects: 359

Group type: COMPARATOR
Intervention: 6HE2/3H2 (control for non‐complicated forms)
Number of subjects: 359

Group type: COMPARATOR
Intervention: 3HES2/3HE2/3H2 (control for complicated forms)
Number of subjects: 359
Study: 6294004

Group type: EXPERIMENTAL
Intervention: Increased carbohydrate intake from 200 to 400 g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-fibre diet rich in beans and lentils
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Increase of dietary fibre to 50 g mainly as cereal fibre
Number of subjects: 6
Study: 30852397

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29106978

Group type: EXPERIMENTAL
Intervention: The COACH Program (4 or more coaching sessions)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: The COACH Program (up to 3 coaching sessions)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: The COACH Program
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: The COACH Program (males)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 512
Study: 26433700

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Healthy participants (control group)
Number of subjects: 41
Study: 24002616

Group type: EXPERIMENTAL
Intervention: Health coaches providing weight loss counseling
Number of subjects: 26
Study: 22057652

Group type: EXPERIMENTAL
Intervention: Thiamine (300 mg/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 19605370

Group type: EXPERIMENTAL
Intervention: Recombinant human relaxin
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Type I oral collagen
Number of subjects: 328

Group type: COMPARATOR
Intervention: Total MRSS
Number of subjects: 328
Study: 16755104

Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended adjuvant therapy, selection of responders using array-based techniques, combination therapy with signal transduction inhibitors
Number of subjects: 0
Study: 14690340

Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10992952

Group type: EXPERIMENTAL
Intervention: Daily practice of three visual tasks (fixation, saccade, and distractor conditions) for 3 to 8 weeks
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 85
Study: 8865709

Group type: EXPERIMENTAL
Intervention: 150 ml oral water
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 150 ml refreshing drink
Number of subjects: 45

Group type: COMPARATOR
Intervention: No fluid (control)
Number of subjects: 45
Study: 1624025

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 1.88 mg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 3.75 mg
Number of subjects: 41
Study: 6084920

Group type: EXPERIMENTAL
Intervention: Griseofulvin plus Levamisole
Number of subjects: 26

Group type: COMPARATOR
Intervention: Griseofulvin plus Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Specific TR antigen extract stimulation
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Immediate weal reactions to TR extract
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Increased concentration of IgE antibodies
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Specific IgG antibodies towards TR
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Presence of specific IgG antibodies and strong specific cellular immune response
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Environmental factors and atopy
Number of subjects: 26
Study: 30628073

Group type: EXPERIMENTAL
Intervention: 100% O2 (hyperoxia)
Number of subjects: 33

Group type: COMPARATOR
Intervention: 21% O2 (normoxia)
Number of subjects: 33
Study: 28118549

Group type: EXPERIMENTAL
Intervention: Lower-target group (80 to 110 mg/dL)
Number of subjects: 713

Group type: COMPARATOR
Intervention: Higher-target group (150 to 180 mg/dL)
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Lower-target group
Number of subjects: 713

Group type: COMPARATOR
Intervention: Higher-target group
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 713
Study: 26009989

Group type: EXPERIMENTAL
Intervention: 3 weeks of oral antibiotic treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 6 weeks of oral antibiotic treatment
Number of subjects: 40
Study: 23647409

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 21757386

Group type: EXPERIMENTAL
Intervention: Intensive periodontal therapy (IPT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control periodontal therapy (CPT)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Intensive periodontal therapy (IPT) in type 2 DM
Number of subjects: 93
Study: 19909203

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU)
Number of subjects: 40
Study: 16506873

Group type: EXPERIMENTAL
Intervention: Errorless (implicit) learning strategy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Discovery (explicit) learning strategy
Number of subjects: 22
Study: 14747190

Group type: EXPERIMENTAL
Intervention: GnRH analogue (3.75 mg/28 days leuprolide acetate depot) with raloxifene (60 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (1 tablet/day)
Number of subjects: 100
Study: 11574796

Group type: EXPERIMENTAL
Intervention: Diaspirin cross-linked hemoglobin (DCLHb)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 112
Study: 9508163

Group type: EXPERIMENTAL
Intervention: More extensive radiotherapy
Number of subjects: 3888

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus chemotherapy
Number of subjects: 3888
Study: 7848587

Group type: EXPERIMENTAL
Intervention: Sulfuric acid (H2SO4) aerosol (100 micrograms/m3) followed by ozone exposure at 0.08, 0.12, or 0.18 ppm
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium chloride (NaCl) aerosol (control) followed by ozone exposure at 0.08, 0.12, or 0.18 ppm
Number of subjects: 60
Study: 2898025

Group type: EXPERIMENTAL
Intervention: Intensified diabetic control with continuous subcutaneous insulin infusion (CSII)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional injection treatment
Number of subjects: 68
Study: 30370503

Group type: EXPERIMENTAL
Intervention: Hypothetical above average pharmacogenetic response to smoking cessation medication
Number of subjects: 474

Group type: COMPARATOR
Intervention: Hypothetical below average pharmacogenetic response to smoking cessation medication
Number of subjects: 474
Study: 28969404

Group type: EXPERIMENTAL
Intervention: Green tea catechins (600 mg daily for 1 year)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Green tea catechins
Number of subjects: 60
Study: 26242893

Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate (6mg)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Single-dose radiotherapy (8 Gy)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Retreatment patients
Number of subjects: 470
Study: 23931038

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 3800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3800
Study: 20563553

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided infiltration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional palpation technique
Number of subjects: 60
Study: 18418314

Group type: EXPERIMENTAL
Intervention: Contrast media
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antioxidant therapy, hydration regimens, choice of contrast agents
Number of subjects: 0
Study: 17165278

Group type: EXPERIMENTAL
Intervention: Mometasone furoate DPI 100 microg every evening
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Mometasone furoate DPI 100 microg twice daily
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Mometasone furoate DPI (both doses)
Number of subjects: 296
Study: 12666704

Group type: EXPERIMENTAL
Intervention: GTR + CPF
Number of subjects: 10

Group type: COMPARATOR
Intervention: CPF
Number of subjects: 10
Study: 11069325

Group type: COMPARATOR
Intervention: Dual therapy (lansoprazole 30 mg o.d. plus amoxicillin 750 mg b.d.)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Dual therapy plus ecabet sodium (1 g b.d.)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Dual therapy plus ecabet sodium (2 g b.d.)
Number of subjects: 71
Study: 9059199

Group type: EXPERIMENTAL
Intervention: Ketoprofen 1 mg kg-1 i.v. after induction followed by an infusion of ketoprofen 1 mg kg-1 over 2 h
Number of subjects: 164

Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 164
Study: 8419248

Group type: EXPERIMENTAL
Intervention: Propofol (1.5 mL = 15 mg)
Number of subjects: 10
Study: 3476237

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (once every 3 months)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Fluoride mouthrinse (once a week)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (for home care)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo mouthrinse (once a week)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo dentifrice (for home care)
Number of subjects: 252
Study: 29473357

Group type: EXPERIMENTAL
Intervention: Zheng's stunt needling technique
Number of subjects: 166

Group type: COMPARATOR
Intervention: Traditional even needling technique
Number of subjects: 166
Study: 27130793

Group type: EXPERIMENTAL
Intervention: Hormonal therapy plus radiation therapy to 70 Gy
Number of subjects: 880

Group type: COMPARATOR
Intervention: Hormonal therapy alone
Number of subjects: 880
Study: 24160900

Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 25

Group type: COMPARATOR
Intervention: No text message reminders (control group)
Number of subjects: 25
Study: 22067254

Group type: EXPERIMENTAL
Intervention: MagPro™ (Mg cream)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 19827500

Group type: EXPERIMENTAL
Intervention: Standardized home exercise program for acute inversion sprain
Number of subjects: 22
Study: 17459550

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 42
Study: 15782878

Group type: EXPERIMENTAL
Intervention: Use of forms to record residents' wishes about end of life care
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Palliative care policy implementation
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Formal advance directive requirement
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Proxy appointment for residents
Number of subjects: 69
Study: 12175666

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 1018
Study: 9718789

Group type: EXPERIMENTAL
Intervention: Trabucco repair
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bassini technique
Number of subjects: 80
Study: 7663909

Group type: EXPERIMENTAL
Intervention: Transrectal ultrasonography (TRUS) guidance
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Digitally guided systematic biopsies
Number of subjects: 52
Study: 2262897

Group type: EXPERIMENTAL
Intervention: Atropine 0.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine 1.0 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine 2.0 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine 4.0 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 65513

Group type: EXPERIMENTAL
Intervention: Pethidine (meperidine) with phenobarbitone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Pethidine (meperidine) without phenobarbitone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Phenobarbitone pretreatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30557230

Group type: EXPERIMENTAL
Intervention: Home-based cognitive prehabilitation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 61
Study: 28252875

Group type: EXPERIMENTAL
Intervention: Topical diclofenac (0.1%) four times a day for 7 days before surgery and discontinued 30 days after surgery
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Topical diclofenac (0.1%)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 24874561

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV) via RAM NC
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure ventilation (NCPAP) via RAM NC
Number of subjects: 88
Study: 23144450

Group type: EXPERIMENTAL
Intervention: Pegloticase 8 mg biweekly
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Pegloticase 8 mg monthly
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Pegloticase treatment
Number of subjects: 149
Study: 21448308

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (2 x 100 mg) and tramadol (4 x 100 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group received tramadol (4 x 100 mg)
Number of subjects: 40
Study: 19257824

Group type: EXPERIMENTAL
Intervention: Ibandronate (IBN) 2 mg intravenously every 3 months
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (CTR)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ibandronate (IBN)
Number of subjects: 35
Study: 16959931

Group type: EXPERIMENTAL
Intervention: Nurse-led, home-based case management intervention
Number of subjects: 147

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 147
Study: 16015459

Group type: EXPERIMENTAL
Intervention: Autogenic training (AT) for 10 weeks, with weekly sessions and daily practice at home
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study: 12581053

Group type: EXPERIMENTAL
Intervention: Boost intervention in conservative treatment
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard conservative treatment
Number of subjects: 2
Study: 9924166

Group type: EXPERIMENTAL
Intervention: Emergency revascularization (via percutaneous transluminal coronary angioplasty or coronary artery bypass grafting)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial medical stabilization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emergency revascularization
Number of subjects: 0
Study: 7558772

Group type: EXPERIMENTAL
Intervention: Associate learning subtest from the Wechsler Memory Scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benton's Visual Retention test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled Word Association Task (FAS)
Number of subjects: 0
Study: 2374076

Group type: EXPERIMENTAL
Intervention: Rehearsal-plus
Number of subjects: 42

Group type: COMPARATOR
Intervention: Traditional
Number of subjects: 42

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 42
Study: 7294327

Group type: EXPERIMENTAL
Intervention: Physostigmine 2 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no physostigmine)
Number of subjects: 32
Study: 31386821

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT), performed three days per week for four weeks, consisting of cycling bouts of 30 s each at 80% MAP, followed by four minutes of recovery at 40% MAP.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (n=8)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both groups performed a graded exercise test (GXT) before and after the intervention.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 17
Study: 29486960

Group type: EXPERIMENTAL
Intervention: Active rTMS (20Hz)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 27
Study: 28455597

Group type: EXPERIMENTAL
Intervention: Digitalis treatment
Number of subjects: 27673
Study: 25533872

Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study: 21561791

Group type: EXPERIMENTAL
Intervention: Continuous androgen deprivation therapy (CAD)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation therapy (IAD)
Number of subjects: 193
Study: 20948238

Group type: EXPERIMENTAL
Intervention: Nilvadipine 4 mg/day for ≥30 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (tocopherol nicotinate 300 mg/day, helenien 15 mg/day, or no medication) for ≥30 months
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nilvadipine 4 mg/day for total observational period
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group for total observational period
Number of subjects: 33
Study: 18329587

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 0
Study: 16458337

Group type: COMPARATOR
Intervention: Co-trimoxazole prophylaxis (sulphamethoxazole 800 mg/trimethoprim 160 mg daily)
Number of subjects: 533
Study: 14690096

Group type: EXPERIMENTAL
Intervention: Fentanyl 7 microg kg(‐1)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 10617532

Group type: EXPERIMENTAL
Intervention: Tracker trials
Number of subjects: 0
Study: 8639444

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) 0.3 microgram/kg infused over 30 min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1451052

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 5‐fluorouracil (1000 mg/m2 for 48 hours)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bolus injection of 5‐fluorouracil (500 mg/m2 x 2 in 48 hours)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 5‐fluorouracil
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bolus injection of 5‐fluorouracil
Number of subjects: 16
Study: 6148843

Group type: EXPERIMENTAL
Intervention: Therapist-directed prolonged exposure in vivo (PE)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dynamically oriented supportive therapy (ST)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Relaxation therapy (R)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Basal therapy (B)
Number of subjects: 42
Study: 29017811

Group type: EXPERIMENTAL
Intervention: Peer feedback
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Multiple stakeholders separately
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Multiple stakeholders combined
Number of subjects: 79
Study: 29952519

Group type: EXPERIMENTAL
Intervention: 10-degree head-up tilt position
Number of subjects: 44

Group type: COMPARATOR
Intervention: Horizontal position
Number of subjects: 44
Study: 25192478

Group type: EXPERIMENTAL
Intervention: 20-4 group (valve initially set to 20 cm H₂O and gradually reduced to 4 cm H₂O)
Number of subjects: 68

Group type: COMPARATOR
Intervention: 12 group (valve kept at a medium pressure setting of 12 cm H₂O)
Number of subjects: 68